Symptom Science Literature Database©

References from Nausea and Vomiting in Cancer

Abbott, C. (2000). Integration of complementary disciplines into the oncology clinic. Part V. Nutritional counseling. Current Problems in Cancer, 24(5), 242-267.

Abrahm, J. L. (1999). Management of pain and spinal cord compression in patients with advanced cancer. ACP-ASIM End-of-life Care Consensus Panel.

American College of Physicians-American Society of Internal Medicine. Annals of Internal Medicine, 131(1), 37-46.

Anonymous. (2003). Aprepitant (emend) for prevention of nausea and vomiting due to cancer chemotherapy. Medical Letter on Drugs & Therapeutics, 45(1162), 62-63.

Astradsson, E., Granath, L., Heedman, P. A., & Starkhammar, H. (2001). Cancer patients hospitalised for palliative reasons. Symptoms and needs presented at a university hospital. Supportive Care in Cancer, 9(2), 97-102.

Baines, M. J. (2000). Symptom control in advanced gastrointestinal cancer. European Journal of Gastroenterology & Hepatology, 12(4), 375-379.

Balzer, K. M. (2000). Oxaliplatin. A platinum compound for colorectal cancer? Cancer Practice, 8(4), 201-203.

Bartlett, N., & Koczwara, B. (2002). Control of nausea and vomiting after chemotherapy: what is the evidence? Internal Medicine Journal, 32(8), 401-407.

Beaulieu, N. J. (2000). In the med room. Review of antiemetic therapy in adjuvant breast cancer regimens. Innovations in Breast Cancer Care, 5(2), 39-43.

Bender, C. M., McDaniel, R. W., Murphy-Ende, K., Pickett, M., Rittenberg, C. N., Rogers, M. P., et al. (2002). Chemotherapy-induced nausea and vomiting. Clinical Journal of Oncology Nursing, 6(2), 94-102.

Bernhard, J., Maibach, R., Thurlimann, B., Sessa, C., Aapro, M. S., & Swiss Group for Clinical Cancer, R. (2002). Patients' estimation of overall treatment burden: why not ask the obvious?[comment]. Journal of Clinical Oncology, 20(1), 65-72.

Blower, P. R. (2002). 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J, 8(5), 405-414.

Boccia, R. (2002). Improved tolerability of amifostine with rapid infusion and optimal patient preparation. Seminars in Oncology, 29(6 Suppl 19), 9-13.

Bosnjak, S., Radulovic, S., Neskovic-Konstantinovic, Z., & Mitrovic, L. (2000). Patient statement of satisfaction with antiemetic treatment is related to quality of life. American Journal of Clinical Oncology, 23(6), 575-578.

Bruera, E., & Beattie-Palmer, L. N. (2001). Pharmacologic management of nonpain symptoms in surgical patients. Surgical Oncology Clinics of North America, 10(1), 89-107.

Bruera, E., & Castro, M. (2003). Cannabinoids in supportive care: are they necessary?[comment]. Supportive Care in Cancer, 11(3), 133-134.

Bryant, R. (2003). Managing side effects of childhood cancer treatment. Journal of Pediatric Nursing, 18(2), 113-125.

Buchsel, P. C., Forgey, A., Grape, F. B., & Hamann, S. S. (2002). Granulocyte macrophage colony-stimulating factor: current practice and novel approaches. Clinical Journal of Oncology Nursing, 6(4), 198-205.

Burchett, K. D., & Carungi, R. S. (1999). Gastric leiomyosarcoma presenting as a sentinel hemorrhage. Journal of the American Osteopathic Association, 99(10), 533-536.

Buzdar, A., & Howell, A. (2001). Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clinical Cancer Research, 7(9), 2620-2635.

Caffo, O., Amichetti, M., Mussari, S., Romano, M., Maluta, S., Tomio, L., et al. (2003). Physical side effects and quality of life during postoperative radiotherapy for uterine cancer. Prospective evaluation by a diary card. Gynecologic Oncology, 88(3), 270-276.

Cassidy, J., & Misset, J. L. (2002). Oxaliplatin-related side effects: characteristics and management. Seminars in Oncology, 29(5 Suppl 15), 11-20.

Cella, D., Paul, D., Yount, S., Winn, R., Chang, C. H., Banik, D., et al. (2003). What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN).[comment]. Cancer Investigation, 21(4), 526-535.

Chang, V. T., Hwang, S. S., & Feuerman, M. (2000). Validation of the Edmonton Symptom Assessment Scale. Cancer, 88(9), 2164-2171.

Chang, V. T., & Ingham, J. (2003). Symptom control. Cancer Investigation, 21(4), 564-578.

Chen, X., & Yang, C. S. (2001). Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis, 22(8), 1119-1129.

Cherny, N. I., Catane, R., European Society of Medical Oncology Taskforce on, P., & Supportive, C. (2003). Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer: report on a survery by the European Society of Medical Oncology Taskforce on Palliative and Supportive Care. Cancer, 98(11), 2502-2510.

Choi, Y. S., & Billings, J. A. (2002). Changing perspectives on palliative care. Oncology (Huntington), 16(4), 515-522; discussion 522-517.

Choi, Y. S., & Billings, J. A. (2002). Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. Journal of Pain & Symptom Management, 24(1), 71-90.

Christman, N. J., Oakley, M. G., & Cronin, S. N. (2001). Developing and using preparatory information for women undergoing radiation therapy for cervical or uterine cancer. Oncology Nursing Forum, 28(1), 93-98.

Cohen, I. J. (2000). What really bothers oncology patients. Pediatric Hematology & Oncology, 17(6), 439-440.

Collins, J. J., Byrnes, M. E., Dunkel, I. J., Lapin, J., Nadel, T., Thaler, H. T., et al. (2000). The measurement of symptoms in children with cancer. Journal of Pain & Symptom Management, 19(5), 363-377.

Conio, M., Filiberti, R., Blanchi, S., & Giacosa, A. (2001). Carditis, intestinal metaplasia and adenocarcinoma of oesophagogastric junction. European Journal of Cancer Prevention, 10(6), 483-487.

Cope, D. (2003). Oncology Patient Evidence-Based Notes (OPEN): antiemetics for chemotherapy-induced nausea and vomiting. Clinical Journal of Oncology Nursing, 7(4), 461-462.

Cowan, J. D., & Palmer, T. W. (2002). Practical guide to palliative sedation. Curr Oncol Rep, 4(3), 242-249.

Cunningham, D., Zalcberg, J., Maroun, J., James, R., Clarke, S., Maughan, T. S., et al. (2002). Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials. European Journal of Cancer, 38(4), 478-486.

Davis, M. P., & Walsh, D. (2000). Treatment of nausea and vomiting in advanced cancer. Supportive Care in Cancer, 8(6), 444-452.

de Wit, R., Herrstedt, J., Rapoport, B., Carides, A. D., Carides, G., Elmer, M., et al. (2003). Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.[see comment]. Journal of Clinical Oncology, 21(22), 4105-4111.

de Wit, R., Herrstedt, J., Rapoport, B., Carides, A. D., Guoguang-Ma, J., Elmer, M., et al. (2004). The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. European Journal of Cancer, 40(3), 403-410.

Docherty, S. L. (2003). Symptom experiences of children and adolescents with cancer. Annual Review of Nursing Research, 21, 123-149.

Douillard, J. Y., Eckardt, J., & Scagliotti, G. V. (2002). Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer, 38(Suppl 4), 21-28.

Dupuis, L. L., & Nathan, P. C. (2003). Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Pediatric Drugs, 5(9), 597-613.

Egerer, G., Hegenbart, U., Salwender, H. J., Goldschmidt, H., & Ho, A. D. (2000). Treatment of chemotherapy-induced emesis. Antibiotics & Chemotherapy, 50, 171-183.

Eisenberg, P., Figueroa-Vadillo, J., Zamora, R., Charu, V., Hajdenberg, J., Cartmell, A., et al. (2003). Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer, 98(11), 2473-2482.

Eremita, D. (2001). Dolasetron for chemo nausea. Rn, 64(3), 38-40.

Fitzpatrick, T. M., & Blair, E. A. (2000). Upper airway complications of smoking. Clinics in Chest Medicine, 21(1), 147-157, x.

Gadducci, A., Cosio, S., Fanucchi, A., & Genazzani, A. R. (2001). Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. Anticancer Research, 21(4B), 2941-2947.

Geels, P., Eisenhauer, E., Bezjak, A., Zee, B., & Day, A. (2000). Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. Journal of Clinical Oncology, 18(12), 2395-2405.

Genre, D., Protiere, C., Macquart-Moulin, G., Gravis, G., Camerlo, J., Alzieu, C., et al. (2002). Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: impact of length of cycles. Supportive Care in Cancer, 10(3), 222-230.

Goldstein, F. J. (2002). Adjuncts to opioid therapy. Journal of the American Osteopathic Association, 102(9 Suppl 3), S15-21.

Goodin, S., & Cunningham, R. (2002). 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist, 7(5), 424-436.

Gralla, R. J. (2002). New agents, new treatment, and antiemetic therapy. Seminars in Oncology, 29(1 Suppl 4), 119-124.

Grant, M., & Kravits, K. (2000). Symptoms and their impact on nutrition. Seminars in Oncology Nursing, 16(2), 113-121.

Gridelli, C., Maione, P., & Rossi, A. (2003). Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?[comment]. Journal of Clinical Oncology, 21(21), 4066-4067; author reply 4067-4068.

Guren, M. G., Dueland, S., Skovlund, E., Fossa, S. D., Poulsen, J. P., & Tveit, K. M. (2003). Quality of life during radiotherapy for rectal cancer. European Journal of Cancer, 39(5), 587-594.

Gutstein, H. B. (2003). Mechanisms underlying cancer-induced symptoms. Drugs of Today, 39(10), 815-822.

Guttuso, T., Jr., Roscoe, J., & Griggs, J. (2003). Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet, 361(9370), 1703-1705.

Halperin, E. C., Watson, D. M., & George, S. L. (2001). Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. Cancer, 91(8), 1444-1450.

Handel, D. L. (2001). Complementary therapies for cancer patients: what works, what doesn't, and how to know the difference. Texas Medicine, 97(2), 68-73.

Heedman, P. A., & Strang, P. (2001). Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Research, 21(6A), 4077-4082.

Hershman, J. M. (1999). Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Thyroid, 9(7), 653-657.

Hesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., de Wit, R., et al. (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.[see comment]. Journal of Clinical Oncology, 21(22), 4112-4119.

Hickok, J. T., Roscoe, J. A., Morrow, G. R., King, D. K., Atkins, J. N., & Fitch, T. R. (2003). Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer, 97(11), 2880-2886.

Hongo, T., Watanabe, C., Okada, S., Inoue, N., Yajima, S., Fujii, Y., et al. (2003). Analysis of the circumstances at the end of life in children with cancer: symptoms, suffering and acceptance. Pediatrics International, 45(1), 60-64.

Horiot, J. C., & Aapro, M. (2004). Treatment implications for radiation-induced nausea and vomiting in specific patient groups. European Journal of Cancer, 40(7), 979-987.

Ihbe-Heffinger, A., Ehlken, B., Bernard, R., Berger, K., Peschel, C., Eichler, H. G., et al. (2004). The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Annals of Oncology, 15(3), 526-536.

Irwin, M. L., & Ainsworth, B. E. (2004). Physical activity interventions following cancer diagnosis: methodologic challenges to delivery and assessment. Cancer Investigation, 22(1), 30-50.

Kaplow, R. (2001). Special nursing considerations. Critical Care Clinics, 17(3), 769-789.

Katz, N. (2002). Coxibs: Evolving role in pain management. Seminars in Arthritis & Rheumatism, 32(3 Suppl 1), 15-24.

Keefe, D. L. (2002). The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist, 7(1), 65-72.

Kemper, K. J., & Wornham, W. L. (2001). Consultations for holistic pediatric services for inpatients and outpatient oncology patients at a children's hospital. Archives of Pediatrics & Adolescent Medicine, 155(4), 449-454.

Kim, Y., & Morrow, G. R. (2003). Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Supportive Care in Cancer, 11(3), 171-177.

Klepstad, P., Borchgrevink, P. C., & Kaasa, S. (2000). Effects on cancer patients' health-related quality of life after the start of morphine therapy. Journal of Pain & Symptom Management, 20(1), 19-26.

Koffman, J., Higginson, I. J., & Donaldson, N. (2003). Symptom severity in advanced cancer, assessed in two ethnic groups by interviews with bereaved family members and friends. Journal of the Royal Society of Medicine, 96(1), 10-16.

Kraut, L., & Fauser, A. A. (2001). Anti-emetics for cancer chemotherapy-induced emesis: Potential of alternative delivery systems. Drugs, 61(11), 1553-1562.

Kris, M. G. (2003). Why do we need another antiemetic? Just ask.[comment]. Journal of Clinical Oncology, 21(22), 4077-4080.

Larrison, E. H. (1999). Management of side effects in patients with recurrent ovarian cancer. Seminars in Oncology, 26(1 Suppl 1), 15-31.

Lundstrom, S., & Furst, C. J. (2003). Symptoms in advanced cancer: relationship to endogenous cortisol levels. Palliative Medicine, 17(6), 503-508.

MacDougall, M. K., LeGrand, S. B., & Walsh, D. (2000). Symptom control in the pregnant cancer patient. Seminars in Oncology, 27(6), 704-711.

Marsden, D. E., Lickiss, J. N., & Hacker, N. F. (2001). Gastrointestinal problems in patients with advanced gynaecological malignancy. Best Practice & Research in Clinical Obstetrics & Gynaecology, 15(2), 253-263.

McCabe, H. L., & Maraveyas, A. (2003). Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy-induced emesis (DCIE). Anticancer Research, 23(6D), 5209-5212.

McClure, S. L., Valentine, J., & Gordon, K. B. (2002). Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Safety, 25(13), 913-927.

Mechoulam, R., & Hanu, L. (2001). The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Research & Management, 6(2), 67-73.

Mercadante, S., Casuccio, A., & Fulfaro, F. (2000). The course of symptom frequency and intensity in advanced cancer patients followed at home. Journal of Pain & Symptom Management, 20(2), 104-112.

Meuser, T., Pietruck, C., Radbruch, L., Stute, P., Lehmann, K. A., & Grond, S. (2001). Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain, 93(3), 247-257.

Miller, M., & Kearney, N. (2004). Chemotherapy-related nausea and vomiting - past reflections, present practice and future management. European Journal of Cancer Care, 13(1), 71-81.

Morrow, G. R., Roscoe, J. A., Hickok, J. T., Andrews, P. R., & Matteson, S. (2002). Nausea and emesis: evidence for a biobehavioral perspective. Supportive Care in Cancer, 10(2), 96-105.

Muijsers, R. B., & Wagstaff, A. J. (2001). Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs, 61(15), 2289-2307.

Muir, J. C., & von Gunten, C. F. (2001). Abdominal cancer, nausea, and vomiting. Journal of Palliative Medicine, 4(3), 391-394.

Mundy, E. A., DuHamel, K. N., & Montgomery, G. H. (2003). The efficacy of behavioral interventions for cancer treatment-related side effects. Seminars in Clinical Neuropsychiatry, 8(4), 253-275.

Nash, C. L., & Gerdes, H. (2002). Methods of palliation of esophageal and gastric cancer. Surgical Oncology Clinics of North America, 11(2), 459-483, xiii.

Osoba, D. (2000). Health-related quality-of-life assessment in clinical trials of supportive care in oncology. Supportive Care in Cancer, 8(2), 84-88.

Park, V. J., & Trovato, J. A. (2004). Frequency of nausea and vomiting after chemotherapy. American Journal of Health-System Pharmacy, 61(7), 722-723.

Passik, S. D., Kirsh, K. L., Rosenfeld, B., McDonald, M. V., & Theobald, D. E. (2001). The changeable nature of patients' fears regarding chemotherapy: implications for palliative care. Journal of Pain & Symptom Management, 21(2), 113-120.

Passik, S. D., Kirsh, K. L., Theobald, D. E., Dickerson, P., Trowbridge, R., Gray, D., et al. (2003). A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. Journal of Pain & Symptom Management, 25(5), 485-488.

Phillips, G. L., 2nd. (2002). The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Seminars in Oncology, 29(6 Suppl 19), 53-56.

Post-White, J., Kinney, M. E., Savik, K., Gau, J. B., Wilcox, C., & Lerner, I. (2003). Therapeutic massage and healing touch improve symptoms in cancer. Integrative Cancer Therapies, 2(4), 332-344.

Radbruch, L., & Vielvoye-Kerkmeer, A. (2003). Buprenorphine TDS: the clinical development rationale and results. International Journal of Clinical Practice Supplement(133), 15-18; discussion 23-14.

Rawlinson, F. (2001). Malignant bowel obstruction. European Journal of Palliative Care, 8(4), 137-140.

Redd, W. H., Montgomery, G. H., & DuHamel, K. N. (2001). Behavioral intervention for cancer treatment side effects. Journal of the National Cancer Institute, 93(11), 810-823.

Rhodes, V. A., McDaniel, R. W., Homan, S. S., Johnson, M., & Madsen, R. (2000). An instrument to measure symptom experience. Symptom occurrence and symptom distress. Cancer Nursing, 23(1), 49-54.

Roscoe, J. A., Morrow, G. R., Hickok, J. T., Bushunow, P., Pierce, H. I., Flynn, P. J., et al. (2003). The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of

Rochester Cancer Center Community Clinical Oncology Program multicenter study. Journal of Pain & Symptom Management, 26(2), 731-742.

Rothenberg, M. L. (2002). Current status of capecitabine in the treatment of colorectal cancer. Oncology (Huntington), 16(12 Suppl No 14), 16-22.

Ruoff, G., & Lema, M. (2003). Strategies in pain management: new and potential indications for COX-2 specific inhibitors. Journal of Pain & Symptom Management, 25(2 Suppl), S21-31.

Schneider, S. M. (1999). I look funny and I feel bad. Measurement of symptom distress. Journal of Child & Family Nursing, 2(5), 380-384.

Schnell, F. M. (2003). Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist, 8(2), 187-198.

Schwenka, J., & Ignoffo, R. J. (2000). Temozolomide. A new option for high-grade astrocytomas. Cancer Practice, 8(6), 311-313.

Sheehan, M. K., Beck, K., Pickleman, J., & Aranha, G. V. (2003). Spectrum of cystic neoplasms of the pancreas and their surgical management. Archives of

Surgery, 138(6), 657-660; discussion 660-652.

Shukla, Y., & Pal, S. K. (2004). Complementary and alternative cancer therapies: past, present and the future scenario. Asian Pacific Journal of Cancer Prevention: Apjcp, 5(1), 3-14.

Skinner, J., & Skinner, A. (1999). Levomepromazine for nausea and vomiting in advanced cancer. Hospital Medicine (London), 60(8), 568-570.

Stone, P., Rees, E., & Hardy, J. R. (2001). End of life care in patients with malignant disease. European Journal of Cancer, 37(9), 1070-1075.

Stoodley, M. A., Nguyen, T. P., & Robbins, P. (1999). Familial fatal and near-fatal third ventricle colloid cysts. Australian & New Zealand Journal of Surgery, 69(10), 733-736.

Strasser, F., Sweeney, C., Willey, J., Benisch-Tolley, S., Palmer, J. L., & Bruera, E. (2004). Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. Journal of Pain & Symptom Management, 27(6), 481-491.

Suarez-Almazor, M. E., Newman, C., Hanson, J., & Bruera, E. (2002). Attitudes of terminally ill cancer patients about euthanasia and assisted suicide: predominance of psychosocial determinants and beliefs over symptom distress and subsequent survival. Journal of Clinical Oncology, 20(8), 2134-2141.

Sutton, L. M., Demark-Wahnefried, W., & Clipp, E. C. (2003). Management of terminal cancer in elderly patients. Lancet Oncology, 4(3), 149-157.

Sweeney, C. (2001). History of testicular cancer chemotherapy: maximizing efficacy, minimizing toxicity. Seminars in Urologic Oncology, 19(3), 170-179.

Tavio, M., Milan, I., & Tirelli, U. (2002). Cancer-related fatigue (review). International Journal of Oncology, 21(5), 1093-1099.

Tonini, G., Vincenzi, B., Santini, D., La Cesa, A., Finolezzi, E., Onori, N., et al. (2003). Prevention of radiotherapy-induced emesis. Journal of Experimental & Clinical Cancer Research, 22(1), 17-22.

Treish, I. M. (2000). Targeting leukemia cells with gemtuzumab ozogamicin. Cancer Practice, 8(5), 254-257.

Tremblay, P. B., Kaiser, R., Sezer, O., Rosler, N., Schelenz, C., Possinger, K., et al. (2003). Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. Journal of Clinical Oncology, 21(11), 2147-2155.

van den Bent, M., Chinot, O. L., & Cairncross, J. G. (2003). Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-Oncology, 5(2), 128-138.

Van Fleet, S. (2000). Relaxation and imagery for symptom management: improving patient assessment and individualizing treatment. Oncology Nursing Forum, 27(3), 501-510.

Vickers, A. J., & Cassileth, B. R. (2001). Unconventional therapies for cancer and cancer-related symptoms. Lancet Oncology, 2(4), 226-232.

Wagstaff, A. J., Ibbotson, T., & Goa, K. L. (2003). Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs, 63(2), 217-236.

Walsh, D., Donnelly, S., & Rybicki, L. (2000). The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Supportive Care in Cancer, 8(3), 175-179.

Wang, X. S., Di, L. J., Reyes-Gibby, C. C., Guo, H., Liu, S. J., & Cleeland, C. S. (2004). End-of-life care in urban areas of China: a survey of 60 oncology clinicians. Journal of Pain & Symptom Management, 27(2), 125-132.

Wickham, R. (2004). Management of intractable nausea and vomiting. Clinical Journal of Oncology Nursing, 8(1), 91-94.

Williams, P. D., Ducey, K. A., Sears, A. M., Williams, A. R., Tobin-Rumelhart, S. E., & Bunde, P. (2001). Treatment type and symptom severity among oncology patients by self-report. International Journal of Nursing Studies, 38(3), 359-367.

Willner, J., Schmidt, M., Kirschner, J., Lang, S., Borgmeier, A., Huber, R. M., et al. (2001). Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of stage III inoperable non-small cell lung cancer. Results of a dose escalation study. Lung Cancer, 32(2), 163-171.

Yates, R., Lyons, M., & Horstman, A. (2003). Symptom control in advanced cancer: meeting the challenge. Jaapa/Journal of the American Academy of Physician Assistants, 16(10), 40-42, 45-49.

Yount, S., Cella, D., Webster, K., Heffernan, N., Chang, C., Odom, L., et al. (2002). Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index. Journal of Pain & Symptom Management, 24(1), 32-44.

Zhou, J., Li, Z., & Jin, P. (1999). A clinical study on acupuncture for prevention and treatment of toxic side-effects during radiotherapy and chemotherapy. Journal of Traditional Chinese Medicine, 19(1), 16-21.

Zojer, N., Keck, A. V., & Pecherstorfer, M. (1999). Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Safety, 21(5), 389-406.